Cargando…
Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non–Small Cell Lung Cancer: A Phase 1 Trial
IMPORTANCE: Programmed cell death 1 (PD-1) antibodies have shown substantial survival benefit in patients with advanced non–small cell lung cancer (NSCLC). Toripalimab is a promising and practicable PD-1 antibody; however, its performance in NSCLC has not been established. OBJECTIVES: To assess the...
Autores principales: | Wang, Zhijie, Ying, Jianming, Xu, Jiachen, Yuan, Pei, Duan, Jianchun, Bai, Hua, Guo, Changyuan, Li, Lin, Yang, Zhenlin, Wan, Rui, Fei, Kailun, Zhao, Zhe, Du, Xinyang, Zhao, Junhui, Lv, Ning, Wang, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536589/ https://www.ncbi.nlm.nih.gov/pubmed/33017026 http://dx.doi.org/10.1001/jamanetworkopen.2020.13770 |
Ejemplares similares
-
Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer
por: Zhao, Zhe, et al.
Publicado: (2020) -
A new chapter in immune checkpoint inhibitor therapy: starting with advanced lung squamous cell carcinoma
por: Fei, Kailun, et al.
Publicado: (2020) -
Severe cumulative skin toxicity during toripalimab combined with vemurafenib following toripalimab alone
por: Zhou, Hong, et al.
Publicado: (2023) -
Toripalimab in advanced biliary tract cancer
por: Li, Wei, et al.
Publicado: (2022) -
Multi-omics indicators of long-term survival benefits after immune checkpoint inhibitor therapy
por: Zhao, Jie, et al.
Publicado: (2023)